Singapore, July 1 -- Japan based Santen Pharmaceutical Co., Ltd. and Singapore based Plano Pte. Ltd have announced a strategic alliance to tackle the global burden of myopia.

Under this strategic alliance, Plano has secured an investment from Santen. Santen, through Plano, will initiate to tackle the burden of myopia using both a holistic approach and innovative technological solutions.

Santen, as a leading company in the field of ophthalmology, has cultivated expertise and capabilities specializing in ophthalmology based on a thorough customer orientation, including patients and healthcare professionals.

Plano is an eye health tech company launched in 2017, founded by Associate Professor Mohamed Dirani. It is the first spin-off from t...